Porphyrien

Literatur
1 Doss MO. Hepatic porphyrias: pathobiochemical, diagnostic, and therapeutic implications. Prog Liver Dis 1982; 7: 573-597
2 Stölzel U, Doss M. Porphyrias. In: Dancygier H, , ed Clinical Hepatology, Principles and Practice of Hepatobiliary Diseases. Vol. 2 Berlin: Springer; 2009: 1077-1092
3 Fargion S, Piperno A, Cappellini MD et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322-1326
4 Stölzel U, Köstler E, Koszka C et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21: 1500-1503
5 Whatley SD, Ducamp S, Gouya L et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008; 83: 408-414
6 Bonkovsky HL. Advances in understanding and treating “the little imitator”, acute porphyria. Gastroenterology 1993; 105: 590-594
7 Stölzel U, Doss MO, Dissmann T et al. Gastroenterologic and neurologic manifestations in acute intermittent porphyria. Med Klin (Munich) 1987; 82: 520-525
8 Köstler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 2005; 6: 377-383
9 Puy H, Gouya L. Porphyrias. Lancet 2010; 375: 924-937
10 Doss M, von Tiepermann R et al. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 1979; 57: 1123-1127
11 Anderson KE, Bloomer JR, Bonkovsky HL et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142: 439-450
12 Bonkowsky HL, Tschudy DP, Collins A et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci U S A 1971; 68: 2725-2729
13 Doss M, Verspohl F. The “glucose effect” in acute hepatic porphyrias and in experimental porphyria. Klin Wochenschr 1981; 59: 727-735
14 Handschin C, Lin J, Rhee J et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005; 122: 505-515
15 Stölzel U, Brosche C, Koszka C et al. Safe and probably safe drugs in acute porphyria. Cell Mol Biol 2009; 55: 147-151
16 Seth AK, Badminton MN, Mirza D et al. Liver transplantation for porphyria: who, when, and how?. Liver Transpl 2007; 13: 1219-1227
17 Dowman JK, Gunson BK, Bramhall S et al. Liver transplantation from donors with acute intermittent porphyria. Ann Intern Med 2011; 154: 571-572
18 Ippen H. Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol 1977; 14: 253-259
19 Kordac V, Semradova M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol 1974; 90: 95-100
20 Wollina U, Köstler E, Koch A et al. Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?. Int J Dermatol 2009; 48: 1250-1253
21 Stölzel U, Köstler E, Schuppan D et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003; 139: 309-313
22 Wahlin S, Aschan J, Bjornstedt M et al. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007; 46: 174-179